Prospective Meta-Analysis of Oxygen Saturation Trials in Preterm Infants

早产儿血氧饱和度试验的前瞻性荟萃分析

• 批准号: 8684618
• 负责人: WALDEMAR A. CARLO FONT
• 金额: $ 6.94万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-15 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8684618
• 关键词: Academy; Address; Adverse effects; Age; Age-Months; American; Australia; Birth; Bronchopulmonary Dysplasia; Canada; Cessation of life; Characteristics; Collaborations; Confidence Intervals; Consensus; Data; Data Aggregation; Data Collection; Death Rate; Development; Funding; Individual; Infant; Infant Care; Intention; Intervention; Level of Evidence; Medicine; Meta-Analysis; Modification; Morbidity - disease rate; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Necrotizing Enterocolitis; Neonatal; New Zealand; Outcome; Oxygen; Participant; Patients; Pediatrics; Population; Practice Guidelines; Pregnancy; Premature Infant; Principal Investigator; Public Health; Publishing; Randomized Controlled Trials; Recommendation; Recruitment Activity; Reporting; Research Personnel; Retinopathy of Prematurity; Risk; Risk Factors; Sample Size; Subgroup; Supplementation; Survivors; Testing; United Kingdom; design; disability; group intervention; high risk; improved; innovation; intervention effect; mortality; patient population; primary outcome; prospective; public health relevance

DESCRIPTION (provided by applicant): Preterm infants frequently need oxygen supplementation to survive but it is difficult to determine the precise oxygen saturation levels that optimize outcomes without adverse effects. The NICHD/NHLBI-funded SUPPORT Trial was designed to test the effects of oxygen supplementation using oxygen saturation targets in the recommended range. Four other multicenter randomized controlled trials (BOOST II United Kingdom, BOOST II Australia, BOOST II New Zealand, COT Canada) used the same intervention as SUPPORT as part of a planned prospective analysis. The group formed the Neonatal Oxygenation Prospective Meta-analysis Collaboration (NeOProM) to undertake the first prospective individual participant data meta-analysis in neonatal medicine. The investigators of all the five trials collaborated in the design and data collection so the results could be combined with an individual participant data meta-analysis. Some of these trials indicate that within the levels of oxygen saturations recommended for preterm infants the risks for death, retinopathy of prematurity, bronchopulmonary dysplasia, and necrotizing enterocolitis may differ by oxygen saturation targets. An individual participant meta-analysis of data is essential because the sample size of the combined trials is necessary to detect important outcomes such as death or disability in survivors because the individual trials reported differences in the point estimate and confidence intervals. The prospective design of this individual participant data meta-analysis is innovative and will be one of the first in medicine. The prospective meta- analysis overcomes important limitations inherent to retrospective meta-analysis. The primary outcome that will be assessed is a composite outcome of death or major disability at 18-24 months of age corrected for gestation at birth. It is expected that this prospective individual participant meta-analysis will provide robust and definite results that can drive the field, inform experts and clinicians to develop consensus on recommendations, and improve major outcomes in this high risk population. Preterm infants are an increasingly important public health constituency with high mortality and long-term morbidities that may be reduced by application of the results of the proposed analyses.

描述（由申请人提供）：早产儿经常需要补充氧气才能生存，但很难确定精确的氧饱和度水平，以优化结果而不产生不良影响。 NICHD/NHLBI 资助的支持试验旨在使用推荐范围内的氧饱和度目标来测试补充氧气的效果。其他四项多中心随机对照试验（BOOST II 英国、BOOST II 澳大利亚、BOOST II 新西兰、COT 加拿大）使用与 SUPPORT 相同的干预措施作为计划的前瞻性分析的一部分。该小组成立了新生儿氧合前瞻性荟萃分析合作组织 (NeOProM)，以进行新生儿医学领域的首次前瞻性个体参与者数据荟萃分析。所有五项试验的研究人员在设计和数据收集方面进行了合作，因此结果可以与个体参与者的数据荟萃分析相结合。其中一些试验表明，在为早产儿推荐的氧饱和度水平内，死亡、早产儿视网膜病变、支气管肺发育不良和坏死性小肠结肠炎的风险可能因氧饱和度目标而异。个体参与者对数据的荟萃分析至关重要，因为联合试验的样本量对于检测幸存者的死亡或残疾等重要结果是必要的，因为个体试验报告了点估计和置信区间的差异。这项个体参与者数据荟萃分析的前瞻性设计具有创新性，将成为医学领域的首批设计之一。前瞻性荟萃分析克服了回顾性荟萃分析固有的重要局限性。将评估的主要结局是根据出生时妊娠校正的 18-24 个月龄死亡或严重残疾的综合结局。预计这项前瞻性个体参与者荟萃分析将提供稳健而明确的结果，可以推动该领域的发展，为专家和临床医生提供建议，就建议达成共识，并改善这一高风险人群的主要结果。早产儿是一个日益重要的公共卫生群体，具有高死亡率和长期发病率，通过应用拟议的分析结果可以减少早产儿的死亡率和长期发病率。